Haptoglobin Type Clinical Trial
Official title:
The Type of Hepatoglobin in IUGR
| NCT number | NCT02127385 |
| Other study ID # | 0001-14 |
| Secondary ID | |
| Status | Not yet recruiting |
| Phase | N/A |
| First received | April 29, 2014 |
| Last updated | April 29, 2014 |
| Start date | April 2014 |
| Verified date | March 2014 |
| Source | Hillel Yaffe Medical Center |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Israel: Ministry of Health |
| Study type | Observational |
Intra Uterine Growth Restriction is associated with increased oxidative stress. Haptoglobin (Hp) is an abundant plasma glycoprotein produced in the liver. The function of Hp is as anti oxidant agent, it binds free hemoglobin (Hb) released from red blood cells to decrease oxidative tissue damage. There are 3 differenet genotype of haptoglobin Hp 1-1 Hp 1-2 and Hp 2-2 with different anti oxidant properties and different prevalence ( Hp 1-1, Hp 1-2 and Hp 2-2approximately 16%, 48% and 36% respectively) . we hypotheise that IUGR will be more common and severe in the Hp 2-2 genotype with the less anti oxidant properties.
| Status | Not yet recruiting |
| Enrollment | 200 |
| Est. completion date | |
| Est. primary completion date | April 2015 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Female |
| Age group | 18 Years to 45 Years |
| Eligibility |
Inclusion Criteria: Pregnancies complicated with IUGR - Exclusion Criteria: NOT INTERESTED DO PARTICIPATE |
Observational Model: Case-Only, Time Perspective: Retrospective
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Hillel Yaffe Medical Center |
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | type of haptoglobin | severity of iugr | 10 weeks | No |